Scholtes et al. explored preclinical treatments for the AT-rich interactive domain-containing protein 1A (ARID1A)-deficient bladder cancer using PDOs, identifying ARID1A status as a potential biomarker for personalized therapy [195]. The gene discussed is ARID1A; the disease is urinary bladder cancer.